Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer
about
Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cellsHerbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling.Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast CancerAZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer modelsSimvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from algeria compared with other types of breast cancer tumors.Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer.EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis.Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.Demographic, clinical, pathological, molecular, treatment characteristics and outcomes of nonmetastatic inflammatory breast cancer in Morocco: 2007 and 2008.Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysComparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.Lymph node status in inflammatory breast cancer.How do I treat inflammatory breast cancer?Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population.Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
P2860
Q31138996-D8C37F12-9B1E-45A4-8921-BB5F949E0F00Q33757639-44E58E81-7300-49EE-9340-03782A26D42FQ33760216-02C83869-D14A-48D1-B463-D5A307A1648AQ33770856-E997DE17-0100-4C2F-B222-B6F1C14ADEEDQ33816245-795B4A75-DA83-4D56-9CA3-B8DEED4A8E3FQ34392877-3776BA05-0989-4D24-BBA6-CBE405D39699Q34640608-6A84A6B7-0595-4CDC-ABF4-E7515706F67EQ35183637-438BF838-841C-4835-9F1B-9A521EDD70DBQ35605872-4848C59C-1C40-4448-9993-7F66C4312103Q35701943-5DBCC53C-2D1B-4758-A756-3CF74FFD06FDQ35759050-B4822605-421D-4A44-8842-F81C75FA24A5Q36599823-C314CE15-5A31-4336-A75F-2D64FA9CF12DQ37149249-D8635F43-DE56-4CE1-BE39-FA62CFE545FCQ37431789-14FD66B9-2EE7-44B6-94FE-C85AF1C9F690Q37501320-EDF88D47-DC38-4A02-85D0-F2BCA80F37F1Q37629000-A7EF7B2B-3916-4131-A6F7-40F9D796C394Q37686006-25EB84CD-D87D-49CA-8E62-E84D89BA5679Q37690619-BBBD568B-0F2F-45E6-BB33-E0772BF109B0Q38803734-7436DFBD-27C9-4D8B-AEAF-0132357F0082Q40553911-674C2EE8-58DD-4F97-A63A-D0FD1D0C1C28Q41110592-26DF74CF-9556-415E-A251-7DED305154E3Q44586994-6F1F1FE7-A129-4931-9677-299C5ED16344Q46542099-42ED4A63-D5AA-4147-A450-BE62CC8191A9Q51023485-C1E5D711-6325-4400-B35F-EAB48B810D84Q54967454-738B616A-173B-49FC-9374-33221DD6C583Q55665058-A8BAC875-3738-4867-9271-C4CAF7473D0D
P2860
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Triple-negative subtype predic ...... in inflammatory breast cancer
@ast
Triple-negative subtype predic ...... in inflammatory breast cancer
@en
type
label
Triple-negative subtype predic ...... in inflammatory breast cancer
@ast
Triple-negative subtype predic ...... in inflammatory breast cancer
@en
prefLabel
Triple-negative subtype predic ...... in inflammatory breast cancer
@ast
Triple-negative subtype predic ...... in inflammatory breast cancer
@en
P2093
P2860
P1433
P1476
Triple-negative subtype predic ...... in inflammatory breast cancer
@en
P2093
Ana M Gonzalez-Angulo
Anthony Lucci
Jie S Willey
Massimo Cristofanilli
Melissa L Bondy
Naoto T Ueno
Pamela K Allen
Savitri Krishnamurthy
Thomas A Buchholz
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0196
P577
2011-12-06T00:00:00Z